Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Hematopoietic Cell Transplantation and Cellular Therapy: A New Era
share announcement

Hematopoietic Cell Transplantation and Cellular Therapy: A New Era

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (31 May 2019) | Viewed by 15826

Special Issue Editor

Dr. Celalettin Ustun

E-Mail Website
Guest Editor
Division of Hematology, Oncology and Transplantation, Rush University, 600 S. Paulina St., Chicago, IL 60612, USA
Interests: hematopoietic cell transplantation; allogeneic; graft-versus-host disease; organ-health evaluations before transplantation; alternative donors; cellular therapy

Special Issue Information

Dear Colleagues,

In this Special Issue, we will try to capture all the new and exciting developments in “old” hematopoietic cell transplantation (HCT) and “new” cellular therapy. In HCT, there are significant changes, especially in alternative donors (e.g., haploidentical transplantation and umbilical cord blood (UCB) transplantation). The use of haploidentical transplantation has been increasing while UCB transplantation is declining. However, it does not mean UCB HCT has no place in the HCT world any longer. The differences between UCB HCT immune recovery and other resources could be beneficial. Translational research is still on-going in UCB HCT. What needs to be done to improve haploidentical HCT? There are new, FDA approved drugs for graft-versus-host disease (GVHD) after decades with no development, new agents are actively investigated in GVHD prophylaxis studies. Two industrial CAR T cells have been approved for lymphoid malignancies already. Many studies are underway for patients with hematologic malignancies. What is happening in supportive care, infectious disease relevant to HCT?

In this very exciting era of HCT and cellular therapy, experts will share literature reviews, their own experiences, and comments in this Special Issue.

Dr. Celalettin Ustun
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hematopoietic cell transplantation
  • Cellular therapy
  • Haploidentical transplantation
  • Umbilical cord blood
  • Translational research
  • Graft-versus-host diseases
  • Hematologic malignancies
  • Lymphoid malignancies
  • CAR T cells

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

35 pages, 345 KiB  
Review
Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients
by Carlos A. Q. Santos, Yoona Rhee, Michael T. Czapka, Aamir S. Kazi and Laurie A. Proia
J. Clin. Med. 2020, 9(3), 865; https://doi.org/10.3390/jcm9030865 - 21 Mar 2020
Cited by 7 | Viewed by 4368
Abstract
Hematopoietic stem cell transplant recipients are at increased risk of infection and immune dysregulation due to reception of cytotoxic chemotherapy; development of graft versus host disease, which necessitates treatment with immunosuppressive medications; and placement of invasive catheters. The prevention and management of infections [...] Read more.
Hematopoietic stem cell transplant recipients are at increased risk of infection and immune dysregulation due to reception of cytotoxic chemotherapy; development of graft versus host disease, which necessitates treatment with immunosuppressive medications; and placement of invasive catheters. The prevention and management of infections in these vulnerable hosts is of utmost importance and a key “safety net” in stem cell transplantation. In this review, we provide updates on the prevention and management of CMV infection; invasive fungal infections; bacterial infections; Clostridium difficile infection; and EBV, HHV-6, adenovirus and BK infections. We discuss novel drugs, such as letermovir, isavuconazole, meropenem-vaborbactam and bezlotoxumab; weigh the pros and cons of using fluoroquinolone prophylaxis during neutropenia after stem cell transplantation; and provide updates on important viral infections after hematopoietic stem cell transplant (HSCT). Optimizing the prevention and management of infectious diseases by using the best available evidence will contribute to better outcomes for stem cell transplant recipients, and provide the best possible “safety net” for these immunocompromised hosts. Full article
(This article belongs to the Special Issue Hematopoietic Cell Transplantation and Cellular Therapy: A New Era)
13 pages, 944 KiB  
Review
Pretransplant Cardiac Evaluation Using Novel Technology
by Mohamad Hemu, Allison Zimmerman, Dinesh Kalra and Tochukwu Okwuosa
J. Clin. Med. 2019, 8(5), 690; https://doi.org/10.3390/jcm8050690 - 16 May 2019
Cited by 8 | Viewed by 3129
Abstract
Hematopoietic stem-cell transplantation (HSCT) is a complex procedure that has been increasingly successful in treating malignant and nonmalignant conditions. Despite its effectiveness, it can be associated with potentially life-threatening adverse effects. New onset heart failure, ischemic disease, and arrhythmias are among the most [...] Read more.
Hematopoietic stem-cell transplantation (HSCT) is a complex procedure that has been increasingly successful in treating malignant and nonmalignant conditions. Despite its effectiveness, it can be associated with potentially life-threatening adverse effects. New onset heart failure, ischemic disease, and arrhythmias are among the most notable cardiovascular complications post-HSCT. As a result, appropriate cardiac risk stratification prior to transplant could result in decreased morbidity and mortality by identifying patients with a higher probability of tolerating possible toxicities associated with HSCT. In this review, we aim to discuss the utility of cardiac screening using novel modalities of imaging technology in the pre-HSCT phase. Full article
(This article belongs to the Special Issue Hematopoietic Cell Transplantation and Cellular Therapy: A New Era)
►▼ Show Figures

Figure 1

10 pages, 584 KiB  
Review
Chimeric Antigen Receptor T-Cells: The Future Is Now
by Wassim Mchayleh, Prabhjot Bedi, Rajesh Sehgal and Melhem Solh
J. Clin. Med. 2019, 8(2), 207; https://doi.org/10.3390/jcm8020207 - 7 Feb 2019
Cited by 23 | Viewed by 7995
Abstract
The immune system acting via cancer immune-surveillance is considered a potential target for improving outcomes among some malignancies. The ability to harness immune cells, engineer them and educate them to target cancer cells has changed the paradigm for treating non-Hodgkin’s lymphomas (NHL) and [...] Read more.
The immune system acting via cancer immune-surveillance is considered a potential target for improving outcomes among some malignancies. The ability to harness immune cells, engineer them and educate them to target cancer cells has changed the paradigm for treating non-Hodgkin’s lymphomas (NHL) and acute lymphoblastic leukemia (ALL). Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable anti-tumor activity against refractory B cell malignancies. Ongoing research aims to expand the scope of this adoptive cell therapy, understanding mechanisms of resistance and reducing toxicity. In this review, we will discuss the current scope of CAR T-cell therapy and ongoing future applications. Full article
(This article belongs to the Special Issue Hematopoietic Cell Transplantation and Cellular Therapy: A New Era)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop